Skip to main content
. 2022 Aug 24;158(11):1254–1261. doi: 10.1001/jamadermatol.2022.3516

Table 1. Characteristics of Included Studies.

Source Cohort studies
Database Study period No. of participants, AD/non-AD Age, mean (SD), y Sex, female % Definition of AD VTE, HRs (95% CI) VTE incidence rates per 100 patient-years
Meyers et al,21 2021 IBM MarketScan Commercial Claims and Encounters, Medicare Supplemental, and Medicaid databases 2012-2017 198 685/198 685 46.0 (17.0) 65.2 ICD-9 code 691.8 or ICD-10 code L20.0, L20.8x, L20.9 0.77 (0.69-0.85) 0.24
Schneeweiss et al,22 2021 Optum’s deidentified Clinformatics Data Mart Database 2004-2019 30 418/30 418 47.5 (18.0) 60.8 ICD-9 code 691.8 or ICD-10 code L20, L20.82, L20.84 1.19 (0.95-1.48) 0.18
Source Randomized clinical trials
Clinical trial identifier JAK inhibitor No. of patients with AD, intervention group/control group Age, mean (SD), y Sex, female % Definition of AD Placebo-controlled phase, weeks
Bieber et al,23 2021 NCT03720470 (JADE COMPARE) Abrocitinib 464/131 38.0 (14.7) 51.7 Hanifin and Rajka criteria 12
Blauvelt et al,24 2021 NCT03738397 (Heads up) Upadacitinib 348/344 36.6 (14.6) 47.4 Hanifin and Rajka criteria 24
Blauvelt et al,24 2022 NCT03627767 (JADE REGIMEN) Abrocitinib 531/267 Median (IQR), 29.0 (20-41) 43.9 Hanifin and Rajka criteria 40
Eichenfield et al,26 2021 NCT03796676 (JADE TEEN) Abrocitinib 189/96 Median (IQR), 16.0 (14-17) 46.6 Hanifin and Rajka criteria 12
Gooderham et al,27 2019 NCT02780167 Abrocitinib 211/56 40.4 (16.3) 51.7 Hanifin and Rajka criteria 12
Guttman-Yassky et al,28 2020 NCT02925117 Upadacitinib 126/40 40.0 (15.3) 36.5 Hanifin and Rajka criteria 16
Guttman-Yassky et al,29 2021 NCT03569293 (Measure Up 1) and NCT03607422 (Measure Up 2) Upadacitinib 1124/559 Median (IQR), 33.8 (12-75) 44.0 Hanifin and Rajka criteria 16
Katoh et al,30 2022 NCT03661138 (Rising Up) Upadacitinib 182/90 35.5 (13.0) 24.7 Hanifin and Rajka criteria 24
Reich et al,31 2020 NCT03733301 (BREEZE-AD7) Baricitinib 220/108 33.9 (12.1) 34.1 Diagnostic criteria proposed by AAD guideline 16
Reich et al,32 2021 NCT03568318 (AD Up) Upadacitinib 597/303 Median (IQR), 34.0 (12-74) 38.2 Hanifin and Rajka criteria 16
Silverberg et al,33 2020 NCT03575871 (JADE MONO-2) Abrocitinib 313/78 35.5 (15.3) 41.9 Hanifin and Rajka criteria 12
Simpson et al,34 2020 NCT03349060 (JADE MONO-1) Abrocitinib 310/77 32.8 (16.4) 44.8 Hanifin and Rajka criteria 12
Simpson et al,35 2020 (Simpson 2020a) NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2) Baricitinib 745/493 35.0 (12.8) 37.0 Diagnostic criteria proposed by AAD guideline 16
Simpson et al,36 2021 (Simpson 2020b) NCT03435081 (BREEZE-AD5) Baricitinib 292/146 40.0 (16.0) 50.9 Diagnostic criteria proposed by AAD guideline 16
Zhao et al,37 2021 NCT04162899 SHR0302 70/35 36.9 (14.8) 38.6 Chinese criteria 12

Abbreviations: AAD, American Academy of Dermatology; AD, atopic dermatitis; HR, hazard ratio; ICD, International Classification of Diseases; VTE, venous thromboembolism.